Serum Angiogenin in Inflammatory Bowel Disease
- 72 Downloads
Angiogenesis-promoting cytokines have been suggested to play an important role in inflammatory bowel disease (IBD) since they promote inflammation by increasing vascular permeability and mediate tissue repair by activating fibroblasts. The aim of the present study was to evaluate the serum levels of angiogenin, a potent angiogenic factor, in patients with ulcerative colitis (UC) and Crohn’s disease (CD). Angiogenin serum levels were measured in 154 IBD patients (78 UC and 76 CD), in 18 cases with other causes of intestinal inflammation, and in 84 matched healthy controls using a commercially available enzyme-linked immunosorbent assay. Angiogenin levels were assessed in terms of disease activity, type, localization, and treatment. Mean (±SD) serum angiogenin levels were 526.5 ± 224.1 ng/ml in UC patients, 508.8 ± 228.5 ng/ml in CD patients, 394.6 ± 137.6 ng/ml in healthy controls, and 448.1 ± 167.8 ng/ml in patients with non-IBD intestinal inflammation. A statistically significant difference among the mean levels of angiogenin in the four groups was found (P=0.0003). IBD patients with early disease had a significantly lower mean serum angiogenin compared with patients with late disease (P=0.03). No significant association between angiogenin levels and disease activity, localization, disease type, or treatment was found. Serum angiogenin is elevated in patients with IBD. The increased serum angiogenin suggests that angiogenin may mediate angiogenesis and vascular permeability in the mucosa of patients with IBD.
Unable to display preview. Download preview PDF.